VAXX — Vaxxinity Income Statement
0.000.00%
Last trade - 00:00
- $60.34m
- $45.12m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0.557 | 0.066 | 0 | 0 |
Cost of Revenue | |||||
Gross Profit | 0 | 0.505 | -1.87 | 0 | — |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 13.7 | 32.8 | 125 | 76 | 58.3 |
Operating Profit | -13.7 | -32.3 | -125 | -76 | -58.3 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -14.2 | -40 | -137 | -75.2 | -56.9 |
Provision for Income Taxes | |||||
Net Income After Taxes | -14.2 | -40 | -137 | -75.2 | -56.9 |
Net Income Before Extraordinary Items | |||||
Net Income | -14.2 | -40 | -137 | -75.2 | -56.9 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -14.2 | -40 | -137 | -75.2 | -56.9 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.114 | -0.32 | -1.09 | -0.597 | -0.45 |
Dividends per Share |